Anjan Thakurta

As CSO, Dr. Thakurta will lead the scientific, technological, and research operations of BPGbio to advance the internal pipeline, while working with strategic partners in external innovation. Dr. Thakurta’s leadership and scientific contributions have led to six approved cancer drugs in multiple indications.

Prior to BPGbio, Dr. Thakurta was the Vice President, Translational Medicine at Bristol Myers Squibb where he oversaw the hematological malignancy group. Before BMS, Dr. Thakurta served several leadership roles at Celgene, AstraZeneca and Biogen Idec and the United States National Cancer Institute (NCI) earlier in his career. Dr. Thakurta received his MSc and MTech from Jawaharlal Nehru University and IIT Delhi, India, followed by a doctorate from Cambridge University in Genetics. He received his post-doctoral training at Harvard University in molecular and cellular biology. He is a Visiting Professor at Oxford University, UK.